시장보고서
상품코드
2132888

의약품 등급 프로판설폴락톤 시장 보고서 : 동향, 예측 및 경쟁 분석(-2035년)

Pharmaceutical Grade Propanesulfolactone Market Report: Trends, Forecast and Competitive Analysis to 2035

발행일: | 리서치사: 구분자 Lucintel | 페이지 정보: 영문 150 Pages | 배송안내 : 3일 (영업일 기준)

    
    
    




■ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송일정은 문의해 주시기 바랍니다.

가격
PDF, Excel & 1 Year Online Access (Single User License) help
PDF & Excel 보고서를 1명만 이용할 수 있는 라이선스입니다. 텍스트 등의 Copy & Paste 가능합니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 4,850 금액 안내 화살표 ₩ 6,539,000
PDF, Excel & 1 Year Online Access (2-5 User License) help
PDF & Excel 보고서를 동일 사업장에서 5명까지 이용할 수 있는 라이선스입니다. 텍스트 등의 Copy & Paste 가능합니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,700 금액 안내 화살표 ₩ 9,034,000
PDF, Excel & 1 Year Online Access (Corporate License) help
PDF & Excel 보고서를 동일 기업 내 동일 국가의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트 등의 Copy & Paste 가능합니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,850 금액 안내 화살표 ₩ 11,933,000
PDF, Excel & 1 Year Online Access (Global License) help
PDF & Excel 보고서를 동일 기업(완전 자회사 포함)의 전 세계 모든 분이 이용할 수 있는 라이선스입니다. 텍스트 등의 Copy & Paste 가능합니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 10,000 금액 안내 화살표 ₩ 13,484,000
※ 부가세 별도
한글목차
영문목차

의약품 등급 프로판설폴락톤 시장

세계 의약품 등급 프로판설폴락톤 시장의 전망은 의약품 합성 중간체, 항바이러스제 및 항생제 시장에서 발생하는 기회에 힘입어 유망할 것으로 예상됩니다. 전 세계 의약품 등급 프로판설폴락톤 시장은 2027년 1억 7,500만 달러에서 2035년에는 약 3억 2,400만 달러에 달할 것으로 예상되며, 2027년부터 2035년까지 연평균 성장률(CAGR)은 7.8%를 기록할 것으로 전망됩니다. 이 시장의 주요 성장 촉진요인으로는 의약품 첨가제에 대한 수요 증가, 제형 최적화에 대한 중요성 부각, 그리고 프로판설폴락톤의 채택 확대 등이 꼽힙니다.

  • Lucintel사의 예측에 따르면, 종류별로는 금속 및 유기 불순물의 세정 효율이 뛰어나기 때문에 순도 99% 제품이 예측 기간 동안 높은 성장률을 보일 것으로 전망됩니다.
  • 용도별로는 칩 제조에서 초고순도 웨이퍼에 대한 수요가 확대됨에 따라, 의약품 합성 중간체가 예측 기간 동안 가장 높은 성장률을 보일 것으로 전망됩니다.
  • 지역별로는 북미에서 소비자용 전자기기 및 기타 전자기기에 대한 수요가 증가하고 있어, 예측 기간 동안 가장 높은 성장이 예상됩니다.

의약품 등급 프로판설폴락톤 시장의 새로운 동향

의약품 등급 프로판설폴락톤 시장은 2025년부터 2027년까지 특수 화학제품 공급에서 용도가 제한된 관리형 성장으로 전환될 전망입니다. 수요는 의약품 중간체에서 발생하지만, 배터리 연구 분야에는 더 많은 공급업체가 관심을 보일 것입니다. Lucintel의 시장 전망에 따르면, 고객은 공급업체 인증에 따른 위험을 줄이면서 순도, 추적성 및 지역별 공급 체계를 더욱 중시하게 될 것입니다.

  • 지속가능성 : 2025년 한 해 동안 유럽의 화학제품 구매자들은 용제 감축에 관한 데이터와 폐기물 관리 현황에 대한 증거를 계속해서 요구할 것이며, 제조업체들은 프로판설폴락톤의 환경 부하가 낮은 대체품에 대한 평가를 시작했습니다. 제약 업계의 고객들은 향후 3-5년 동안 환경 보고를 지속적으로 확대할 예정이므로, 이러한 추세는 구매 선호도에 영향을 미칠 것으로 보입니다.
  • 품질 관리의 디지털화 : 2025년까지 전자 분석 증명서, 로트 및 이력 관리, 감사 추적이 요구될 것이며, 21 CFR Part 11이 실험실 관리에 도입되기 시작할 전망입니다. 디지털 품질 관리 시스템을 통해 제품 출하까지 소요되는 시간이 단축되고, 제출 서류의 오류도 감소할 것입니다.
  • 지역별 공급원 다각화 : 2024년 이후의 운송 및 공급망 혼란을 계기로 구매자들이 재검토한 결과, 2025년부터 2027년까지 주요 중간체에 대해 지리적으로 분산된 최소 2개의 공급업체를 인증하게 되었습니다. 이러한 지속적인 노력은 소규모 지역 공급업체를 지원하고, 재고 회복탄력성을 비즈니스 강점으로 삼을 것입니다.
  • 고순도 제품의 맞춤화 : 2026년 의약품 개발이 진전됨에 따라, 사양에 따른 등급 설정 및 수분, 금속, 잔류 용매에 대한 보다 엄격한 기준 설정이 진행되고 있습니다. 맞춤화된 정제 공정은 전환 비용을 높이며, 분석법의 검증(밸리데이션)이 가능한 공급업체에게 유리하게 작용할 것입니다.
  • 공정 자동화 : 차별화된 특수 화학제품 공장에서는 연속 공정 제어 시스템, 자동 투여 및 공간 절약형 생산 유닛의 도입이 시작되고 있습니다. 배치 공정에서 변동성을 10-20% 저감할 수 있는 것으로 알려진 수준의 자동화는 수율 향상, 작업자 안전 및 제품 규제 준수 개선에 활용될 수 있는 제어 시스템 설계의 벤치마크가 될 것입니다.

향후 5년 동안은 범용성이 높은 일반 제품의 생산량 확대를 기다리기보다는, 수익성이 높은 특수 화학제품 시장을 엄선하여 보다 목표가 명확한 성장 전략이 전개될 전망입니다. 의약품에 대한 수요는 계속해서 높고 안정적인 수준을 유지할 전망이며, 시장에서 중요한 차별화 요소는 서비스 인증이 될 것입니다. 특수 화학제품 공급업체는 서류 절차 간소화, 지역 내 안정적인 제품 공급, 그리고 배치 주문에 대한 유연성을 서비스 보증으로 제공함으로써 프리미엄 비즈니스를 확보하게 될 것입니다. 다만, 가격은 여전히 큰 우려 사항이 될 것입니다. 그럼에도 불구하고, 고객은 일정대로, 그리고 납기 준수가 엄격한 생산에 대해 공급 계약을 확실하게 이행하는 서비스 제공업체에 대해 더 높은 충성도를 보일 가능성이 높습니다.

의약품 등급 프로판설폴락톤 시장의 최근 동향

의약품 등급 프로판설폴락톤의 소규모 특수 화학제품 시장은 현재 규제 준수가 지배적이며, 이는 의약품 중간체의 사용 및 엄격하게 관리되는 연구와 연결되어 있습니다. 2025년부터 2027년까지 시장 활동과 수요의 속도가 가속화될 것으로 예상되지만, 아시아에 기반을 둔 생산능력의 존재와 더불어 적합성 평가 프로그램 및 발암성 불순물에 대한 감시 강화로 인해 조달 과정의 복잡성도 증가할 것으로 전망됩니다. Lucintel의 분석에 따르면, 성장은 꾸준할 것으로 보이며, 양적인 확대는 기대되지 않습니다.

  • 규제 강화 : 2025년 ECHA의 물질 심사를 통해 1,3-프로판설톤은 계속해서 발암성 규제 대상이 될 것이며, 불순물 프로파일을 유지·관리할 수 있는 공급업체를 우대하는 방식으로 의약품 등급 원료 공급에 대한 요건이 강화될 전망입니다(2025년 1월).
  • 아시아의 생산능력에 대한 투자 : 2025년 한 해 동안 인도의 API 제조업체들은 여러 대규모 프로젝트(10억 루피 이상)(2025년 6월)를 통해 특수 중간체의 생산능력을 지속적으로 확대했습니다. 지역 생산능력은 향상될 전망이지만, 구매자들은 여전히 인증을 받고 분리된 생산 체계를 요구할 것으로 보입니다.
  • 적격성 평가 파트너 계약 : 2025년 계약 개발 프로그램에서 API 개발 기업은 화학제품 공급업체와 제휴하여 상업적 제조 경로 스크리닝 및 배치 적격성 평가를 위한 프로그램을 시행했습니다(2025년 9월). 이러한 파트너십 계약을 통해 전환 위험 감소와 고객 유지율 향상이 기대됩니다.
  • 분석 기술의 고도화 : 2025년에는 의약품 중간체의 출하 승인을 위한 고분해능 LC-MS 분석 시험이 일반화되어, 여러 연구소에서 ppm(백만 분의 1) 단위의 분석 결과를 보고했습니다(2025년 10월). 이로 인해 불합격률은 상승하겠지만, 더 높은 순도의 원료에 대한 프리미엄 가격 형성이 촉진될 것입니다.
  • 소량 계약 : 2025년, 의약품 중간체 공급에 관한 전문 유통 계약은 25킬로그램 단위의 공급 계약을 포함하도록 확대되었습니다(2025년 11월). 이러한 계약은 인증된 원료의 지속적인 공급에 초점을 맞춘 시장으로의 전환을 나타냅니다.

수요는 광범위하지 않고 특정 분야에 계속 집중될 전망입니다. 의약품 등급 프로판설폴락톤은 API 아웃소싱 수요 확대를 누리고 있지만, 규제상의 제한으로 인해 그 광범위한 채택은 억제되고 있습니다. 불순물을 적절히 관리하고, 안정적인 원료 공급원을 확보하며, 소량 생산능력을 갖춘 공급업체가 가장 많은 사업을 수주하게 될 것입니다. 가장 유망한 상업적 전망은 벌크 상품의 공급이 아니라, 제조 경로의 개발이나 고효능 중간체의 개발에 있습니다. 장기적으로는 시장이 가격보다 문서화된 증명을 더 중요하게 여기게 될 것입니다.

목차

제1장 주요 요약

제2장 시장 개요

제3장 시장 동향과 예측 분석

제4장 세계의 의약품 등급 프로판설폴락톤 시장 : 유형별

제5장 세계의 의약품 등급 프로판설폴락톤 시장 : 용도별

제6장 지역별 분석

제7장 북미의 의약품 등급 프로판설폴락톤 시장

제8장 유럽의 의약품 등급 프로판설폴락톤 시장

제9장 아시아태평양의 의약품 등급 프로판설폴락톤 시장

제10장 RoW의 의약품 등급 프로판설폴락톤 시장

제11장 경쟁 분석

제12장 기회와 전략 분석

제13장 밸류체인 전체의 주요 기업 개요

제14장 부록

KSM 26.09.29

Pharmaceutical Grade Propanesulfolactone Market

The future of the global pharmaceutical grade propanesulfolactone market looks promising with opportunities in the drug synthesis intermediate, antiviral drug, and antibiotic markets. The global pharmaceutical grade propanesulfolactone market is expected to reach an estimated $324 million by 2035 from $175 million in 2027 with a CAGR of 7.8% from 2027 to 2035. The major drivers for this market are increasing demand for pharmaceutical excipients, growing emphasis on drug formulation optimization, and rising adoption of propanesulfolactone.

  • Lucintel forecasts that, within the type category, the purity 99% is expected to witness higher growth over the forecast period due to better cleaning efficiency of metal and organic contaminants
  • Within the application category, the drug synthesis intermediate is expected to witness the highest growth over the forecast period due to greater demand for ultra-clean wafers in the production of chips.
  • In terms of regions, North America is expected to witness the highest growth over the forecast period due to increased demand for consumer electronics and other electronic devices in that region.

Emerging Trends in Pharmaceutical Grade Propanesulfolactone Market

The pharmaceutical grade propanesulfolactone market will experience a shift from specialist chemical supply to controlled application-oriented growth between 2025 and 2027. The demand will be from the pharmaceutical intermediates while battery research will interest more suppliers. Lucintel's market perspective advises that customers will focus more on purity, traceability, and regional supply while reducing the risk of supplier qualification.

  • Sustainability: Throughout 2025, European chemical purchasers continued requesting data for solvent reduction and evidence of controlled waste; manufacturers began assessing lower impact alternatives for propanesulfolactone. This will influence purchasing preferences as pharmaceutical customers will continue to expand their environmental reporting over the next 3 to 5 years.
  • Quality Digitalisation: By 2025, electronic certificates of analysis, batch and genealogy controls, and audit trails are expected, and 21 CFR Part 11 will begin to permeate laboratory controls; digital quality systems will reduce the time to release and filed documentation errors.
  • Regional Supply Diversification: Post 2024 disruptions to shipping, supply chains reviewed by buyers resulted in qualifying at least 2 geographical suppliers for critical intermediates within 2025-2027; this continued focus will support smaller regional suppliers and make inventory resilience a business advantage.
  • High Purity Customization: Specification-based grades, tighter limits for water, metals, and residual solvents, are underway as advancements in pharmaceutical development happen in 2026; Customized purification will raise switching costs and favor suppliers who can validate analytical methods.
  • Process Automation: Differentiated specialty chemical plants have begun to implement continuous process control systems, automated dosing, and small-footprint production units. Automation on a scale where 10-20% reduction in variability is reported for batch processes, provides a benchmark for the design of control systems that can potentially be used to improve yield, worker safety and product regulatory compliance.

The next five years should see a more focused approach to growth through selective higher margin specialty chemical markets, rather than waiting for the more general purpose commodity volume expansions. Demand for pharmaceutical products will remain high and steady, with qualification of services as the key differentiator in the market. Specialty chemical suppliers will gain premium business with a service guarantee of simplified documentation, consistent regional supply of product, and flexibility in batch orders, at a price which will remain a major concern. Despite this, the customers will most likely be more loyal to service providers who reliably meet their supply contracts for consistently scheduled, time-critical production.

Recent Developments in the Pharmaceutical Grade Propanesulfolactone Market

The small specialty chemical market for Pharmaceutical Grade Propanesulfolactone is currently dominated by compliance and tied to the use of pharmaceutical intermediates and tightly controlled research. While the pace of activity and demand is expected to accelerate during 2025 to 2027, so will the complexity of sourcing due to the presence of Asia-based capacity combined with qualification programs and increasing scrutiny of potential carcinogenic impurities. Lucintel's analysis indicates growth will be disciplined and not of a voluminous nature.

  • Regulatory Tightening: Due to 2025 ECHA substance scrutiny, 1,3- propanesultone will remain under carcinogenicity controls, and increased requirements will be placed on the supply of pharmaceutical grade material (January 2025) in the favor of suppliers capable of supporting and maintaining an impurity profile.
  • Investment in Capacity from Asia: Specialty intermediate capacity continued to be added by Indian API manufacturers during 2025 with multiple large projects (greater than ₹100 crore) (June 2025). While regional capacity should improve, buyers will still require qualified, segregated production.
  • Qualification Partner Contracts: In the contract development programs of 2025, API developers partnered with chemical suppliers, resulting in programs for the screening of commercial routes and the batch qualification (September 2025). Such partnership contracts will result in lower switching risk and increased customer retention.
  • Increased Analytical Technology: High-resolution LC-MS analytical testing for the release of pharmaceutical intermediates became common during 2025 with several laboratories reporting the analysis at the parts per million range (October 2025) (October 2025). This will cause an increase in the rejection rate but will support a premium for cleaner material.
  • Small Lot Contracts: 2025 specialty distribution agreements for the supply of pharmaceutical intermediates increased to include contracts for supply of 25 kilogram lots (November 2025). These agreements indicate a shift to a market focused on the recurring supply of qualified material.

Demand will stay focused rather than broader. Pharmaceutical Grade Propanesulfolactone enjoys growing API outsourcing, however regulatory limits curb broad adoption. Suppliers with controlled impurities, assured feedstock, and small lot capabilities will command the most business. The best commercial prospects exist in the development of routes and high-potency intermediates as opposed to bulk commodity supply. The market will favor documentation over price in the long run.

Strategic Growth Opportunities in the Pharmaceutical Grade Propanesulfolactone Market

Between 2024 and 2026, the pharmaceutical-grade propanesulfolactone market is expected to increase as pharmaceutical companies purchase cleaner intermediates, and have a more controlled level of impurities, and more reliable regional supply. Companies place greater emphasis on specialty chemistry. In addition to price, selections of specialty chemistry will be more robust and flexible. Lucintel's perspective on the market suggests that now is the time to assess applications and production technologies, rather than waiting until demand is higher due to volume growth.

  • Advanced Drug Intermediates: Reactive sulfonate intermediates from propanesulfolactone enable the synthesis of novel specialized active pharmaceutical ingredients (API) and research compounds. The FDA received 1,457 abbreviated new drug applications in 2024 (January 2025). It is expected that over the next three to five years, market demand from intensive pipelines of generic drugs and orphan drugs will lead to increased consumption of higher quality products.
  • High-purity Custom Manufacturing: Contract R&D and manufacturing organizations can provide manufacturing services for custom specific grades where the levels of water, metals and solvents were significantly lowered. In 2024, the Chinese pharmaceutical manufacturing revenues reportedly were close to $280 billion (March 2025), providing a strong potential for outsourced manufacturing. Purchasers will pay for batch to batch consistency and thorough documentation rather than a commodity supply.
  • Continuous and Digital Production: Continuous-flow production not only reduces variability and control issues, but also improves safety and variability for reactive sulfonated molecules. In 2025 (April), the European Commission pledged €1.8 billion to support an increase in the resilience of pharmaceutical manufacturing. Digital batch records integrated with process analytical technology (PAT) will facilitate continuous bench scale manufacturing.
  • Regional Supply Expansion: Qualified dual-supply networks may allow local Indian, European, and North American producers to avoid concentration in Asian sourcing. India's pharmaceutical exports amounted to $27.85 billion in Indian fiscal year 2025 (April 2025). Regional qualification programs will offer revenue opportunities to suppliers who are able to fulfill pharmacopoeial testing and delivery requirements.
  • Sustainable Solvent Systems: Customers may distinguish between suppliers through improved synthesis and solvent recovery and through documented carbon footprint reduction. The publication of the revised pharmaceutical legislation by the EU in April 2025 has placed more pressure on companies to fulfill measurable environmental goals. Within three to five years, procurement departments will prefer suppliers who can provide pharmaceutical grade purity and reliable waste and emission data.

Specialized demand will continue to exist, and it will be to the suppliers' advantage. Control of impurity profiles, provision of regulatory support, and the ability to perform process development will result in longer contracts. The best opportunities for growth will no doubt be achieved in custom manufacturing and regional qualification. There will also be increased demand for sustainability in purchasing. Companies who neglect propanesulfolactone as a documented process input will fail to maintain price competitiveness with the growing pharmaceutical development market.

Pharmaceutical Grade Propanesulfolactone Market Drivers and Challenges

Pharmaceutical late stage intermediates are influenced by innovative pharmaceuticals, the flexibility of their manufacturing, regulatory control, and the demand for purer intermediates. Some improvements result in easier synthesis with less steps, while others are a negative consequence of the economics of R&D and manufacturing. Regulations influence the sourcing of raw materials with an increase of quality assurance and supplier controls. The use of pharmaceutical grade intermediates will increase in applications that are a balance of performance, sustainability, innovation, and cost.

The factors responsible for driving this market include:

  • Customer Demands: An increase in spending by the pharmaceutical industry on research and development, more specifically specialty advanced intermediates, creates a demand for propanesulfolactone. The use of propanesulfolactone in higher order synthesis and formulations makes it important for drug developers that it is consistently available. In 2025 it was projected that pharmaceutical research spending would be above $200 billion globally, creating a demand for propanesulfolactone. During the next three to five years it is anticipated that a high demand for specialty therapies, complex drugs, and advanced technologies in the fields of drug development will be sustained, although demand will be directly related to the success of research, regulatory approvals, and commercial scale of production.
  • Technology Improvements: Advancing technologies for organic synthesis, purification, assays, and process controls have increased reproducibility for the production of pharmaceutical grade propanesulfolactone. Manufacturers can utilize process analytics to better control impurities, the water sensitivity inherent in some processes, and process consistency. In 2025, various analytical controls, including chromatography, spectroscopy, and moisture determinations, were employed by the majority of pharmaceutical manufacturers to verify process intermediates. In the next three to five years, newer process technologies should minimize variability in process intermediates and increase process yields, thus making advanced pharmaceutical processes feasible.
  • Regulatory Support: The demand for high quality pharmaceuticals has resulted in systems to support traceability of intermediates to ensure their validation and consistency of manufacture. The emphasis on good manufacturing practices, documentation of processes and associated impurities and qualification of suppliers has resulted in manufacturing specialization, especially in the area of meeting the requirements of pharmaceutical manufacture. In 2025, a majority of manufacturers aligned their operations to the 3 main Quality guidelines of the International Council for Harmonisation, i.e. Q7, Q8, and Q9. In the next three to five years, it is anticipated that regulatory pressures will create greater demand for approved suppliers, thereby resulting in increased market shares of suppliers offering certified manufacture, production controls, and audits.
  • Sustainability: Pharmaceutical producers are moving toward lower solvents consumption, reduced waste, and less energy consumption and carbon emissions. This motivates suppliers to rethink synthesis paths, solvent recovery and better purification for propanesulfolactone. In 2025, such sustainability programs of many pharmaceutical companies focused on reducing a number of environmental parameters (energy, water, waste, emissions). Over the next 3-5 years, the environmentally improved manufacturing will matter when it comes to procurement. It will be particularly relevant to large international clients that have established supplier sustainability requirements.
  • Manufacturing Efficiency: Increased production expenses and concerns related to supply chains push manufacturers toward yield improvement and reduced material losses. Generally, efficient batch production can decrease the cost of producing pharmaceutical grade propanesulfolactone, while ensuring purity and regulatory compliance. In 2025, manufacturers were much more likely to implement the process analytical technology and digital production documentation in order to control multiple critical parameters in real time. Over the next 3-5 years, automation, predictive maintenance, and improved inventory control systems should provide manufacturers that have the ability to rapidly scale up their operations a competitive advantage.

The challenges facing this market include:

  • Complexity of Production: Creating pharmaceutical grade propanesulfolactone is a challenging process requiring control of purity, impurities, moisture, and compliance to exacting requirements of packaging and storage. Even minor variations at any point in the manufacturing and/or refining phases may result in the rejection of that particular batch. In 2025, it was common practice among pharmaceutical suppliers to subject a batch of propanesulfolactone to several rounds of stringent quality control tests before determining it to be fit for sale for a regulated application. In the next 3 - 5 years, this complexity may inhibit new market entrants and sustain prices at levels higher than for industrial grade propanesulfolactone, especially when the customer requires a high level of specification customization, high levels of validation and stringent controls for small volume orders.
  • Regulatory and Qualification Challenges: Potential customers require technical files, certificates of analysis, change control, and supporting stability and audit reports. Qualification hurdles may take many months, and additional client review and validation are required when any changes to the process are effected. In 2025, most pharmaceutical companies conducted rigorous reviews integrating multiple quality and compliance criteria before enabling business with a given supplier. During the next 3 - 5 years, stringent compliance and inspection requirements, coupled with increased documentation, will cause further barriers to entry, slow supplier changes, while established producers with validated quality systems and customer focus will enter the market.
  • Supply Chain and Cost Volatility: The market relies on specialized raw materials, controlled chemical formulation, qualified logistics providers, and reliable packaging systems. There are potential supply chain disruptions due to energy, transportation, geopolitical situations, and upstream chemicals. In 2025, most pharmaceutical manufacturers continued to implement a dual-sourcing strategy with at least two qualified suppliers for critical materials. There is potential that in the next three to five years, demand for resilience may drive regional production and safety stock, though these may increase working capital, qualifications, and the final costs of pharmaceutical grade propanesulfolactone.

The pharmaceutical grade propanesulfolactone market is expected to grow due to advanced synthesis, regulatory disciplines, sustainability programs, and manufacturing improvements. High demand for reliable, high-purity materials is expected to be sustained during the next three to five years. Complex and expensive raw materials coupled with high qualification standards and supply chain unpredictability are expected to restrain capacity and put pricing pressure on suppliers. Those suppliers that are able to provide quality, reliable supply, efficient processes, and flexible documentation, and that cover the gap of the environment impact will experience market growth. It is expected that the growth of the market has more of a specialty, high compliance focus than high volume.

List of Pharmaceutical Grade Propanesulfolactone Market Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. Through these strategies pharmaceutical grade propanesulfolactone market companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the pharmaceutical grade propanesulfolactone market companies profiled in this report include-

  • Changshu Juhe Chemical
  • Broahony Group
  • Wuhan Jihechang New Material
  • Wuhan Pinestone Technology
  • Anhui Meisenbao Technology
  • Jinan Qinmu Fine Chemical
  • Beijing Yuji Science & Technology

Pharmaceutical Grade Propanesulfolactone Market by Segment

The study includes a forecast for the global pharmaceutical grade propanesulfolactone by type, application, and region.

Pharmaceutical Grade Propanesulfolactone Market by Type [Value ($M) from 2019 to 2035]:

  • Purity99%
  • Purity99.9%

Pharmaceutical Grade Propanesulfolactone Market by Application [Value ($M) from 2019 to 2035]:

  • Drug Synthesis Intermediate
  • Antiviral Drug
  • Antibiotic
  • Others

Pharmaceutical Grade Propanesulfolactone Market by Region [Value ($M) from 2019 to 2035]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

Country Wise Outlook for the Pharmaceutical Grade Propanesulfolactone Market

The pharmaceutical grade propanesulfolactone market is a specialised upstream segment that supports electrolyte additives and pharmaceutical intermediates. From 2025 to 2027, manufacturing security policies along with domestic chemical investments and increasingly higher quality requirements will alter sourcing. Based on their latest market analysis, Lucintel states that there are country-level capacity and regulatory aspects during supplier selection.

  • United States: Increased domestication of pharmaceutical manufacturing; The 2025 initiatives of the U.S. Food and Drug Administration (FDA) for advanced manufacturing, and the anticipated effectiveness of negotiated prices for ten selected drugs, likely to take effect in January 2026, is expected to elevate interest for secure and qualified inputs. In response, demand for specialty chemicals manufactured under current Good Manufacturing Practice (cGMP) is expected to grow, thereby supporting localization of critical supply chains.
  • China: Industrial upgrading and supply-chain localization; Chemical producers continue to invest in higher-purity intermediates and export-compliant production. The combination of policy support and established fluorochemical and electrolyte infrastructure are likely to enhance China's role as a low-cost provider of pharmaceutical grade propanesulfolactone.
  • Germany: European pharmaceutical-security measures; Germany's hospital reform package provides €50 billion for a transformation fund, scheduled to be implemented in January 2025. While this package does not explicitly address propanesulfolactone., the intended focus on pharmaceutical production will likely benefit suppliers who can provide quality and regulatory assurances.
  • India: The Production Linked Incentive scheme covers 41 critical key starting materials and drug intermediates. The scheme has been extended through March 2026. This policy focuses on encouraging domestic process development and import substitution. There may potentially be increased demand for high-purity sulfolactone intermediates.
  • Japan: Japan has begun implementing adjustments to drug prices in 2025, which came into effect in April 2025, while the government focuses on building long-term domestic production of essential medicines. These initiatives will support a systematic approach to sourcing higher-specification imported finished propanesulfolactones and validated suppliers over short-term contracts and spot purchases.

Features of the Global Pharmaceutical Grade Propanesulfolactone Market

  • Market Size Estimates: pharmaceutical grade propanesulfolactone market size estimation in terms of value ($B).
  • Trend and Forecast Analysis: Market trends (2019 to 2026) and forecast (2027 to 2035) by various segments and regions.
  • Segmentation Analysis: pharmaceutical grade propanesulfolactone market size by type, application, and region in terms of value ($B).
  • Regional Analysis: pharmaceutical grade propanesulfolactone market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
  • Growth Opportunities: Analysis of growth opportunities in different type, application, and regions for the pharmaceutical grade propanesulfolactone market.
  • Strategic Analysis: This includes M&A, new product development, and competitive landscape of the pharmaceutical grade propanesulfolactone market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

If you are looking to expand your business in this or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the pharmaceutical grade propanesulfolactone market by type (purity99% and purity99.9%), application (drug synthesis intermediate, antiviral drug, antibiotic, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 8 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Market Overview

  • 2.1 Background and Classifications
  • 2.2 Supply Chain

3. Market Trends & Forecast Analysis

  • 3.2 Industry Drivers and Challenges
  • 3.3 PESTLE Analysis
  • 3.4 Patent Analysis
  • 3.5 Regulatory Environment

4. Global Pharmaceutical Grade Propanesulfolactone Market by Type

  • 4.1 Overview
  • 4.2 Attractiveness Analysis by Type
  • 4.3 Purity99%: Trends and Forecast (2019-2035)
  • 4.4 Purity99.9%: Trends and Forecast (2019-2035)

5. Global Pharmaceutical Grade Propanesulfolactone Market by Application

  • 5.1 Overview
  • 5.2 Attractiveness Analysis by Application
  • 5.3 Drug Synthesis Intermediate: Trends and Forecast (2019-2035)
  • 5.4 Antiviral Drug: Trends and Forecast (2019-2035)
  • 5.5 Antibiotic: Trends and Forecast (2019-2035)
  • 5.6 Others: Trends and Forecast (2019-2035)

6. Regional Analysis

  • 6.1 Overview
  • 6.2 Global Pharmaceutical Grade Propanesulfolactone Market by Region

7. North American Pharmaceutical Grade Propanesulfolactone Market

  • 7.1 Overview
  • 7.2 North American Pharmaceutical Grade Propanesulfolactone Market by Type
  • 7.3 North American Pharmaceutical Grade Propanesulfolactone Market by Application
  • 7.4 United States Pharmaceutical Grade Propanesulfolactone Market
  • 7.5 Mexican Pharmaceutical Grade Propanesulfolactone Market
  • 7.6 Canadian Pharmaceutical Grade Propanesulfolactone Market

8. European Pharmaceutical Grade Propanesulfolactone Market

  • 8.1 Overview
  • 8.2 European Pharmaceutical Grade Propanesulfolactone Market by Type
  • 8.3 European Pharmaceutical Grade Propanesulfolactone Market by Application
  • 8.4 German Pharmaceutical Grade Propanesulfolactone Market
  • 8.5 French Pharmaceutical Grade Propanesulfolactone Market
  • 8.6 Spanish Pharmaceutical Grade Propanesulfolactone Market
  • 8.7 Italian Pharmaceutical Grade Propanesulfolactone Market
  • 8.8 United Kingdom Pharmaceutical Grade Propanesulfolactone Market

9. APAC Pharmaceutical Grade Propanesulfolactone Market

  • 9.1 Overview
  • 9.2 APAC Pharmaceutical Grade Propanesulfolactone Market by Type
  • 9.3 APAC Pharmaceutical Grade Propanesulfolactone Market by Application
  • 9.4 Japanese Pharmaceutical Grade Propanesulfolactone Market
  • 9.5 Indian Pharmaceutical Grade Propanesulfolactone Market
  • 9.6 Chinese Pharmaceutical Grade Propanesulfolactone Market
  • 9.7 South Korean Pharmaceutical Grade Propanesulfolactone Market
  • 9.8 Indonesian Pharmaceutical Grade Propanesulfolactone Market

10. ROW Pharmaceutical Grade Propanesulfolactone Market

  • 10.1 Overview
  • 10.2 ROW Pharmaceutical Grade Propanesulfolactone Market by Type
  • 10.3 ROW Pharmaceutical Grade Propanesulfolactone Market by Application
  • 10.4 Middle Eastern Pharmaceutical Grade Propanesulfolactone Market
  • 10.5 South American Pharmaceutical Grade Propanesulfolactone Market
  • 10.6 African Pharmaceutical Grade Propanesulfolactone Market

11. Competitor Analysis

  • 11.1 Product Portfolio Analysis
  • 11.2 Operational Integration
  • 11.3 Porter's Five Forces Analysis
    • Competitive Rivalry
    • Bargaining Power of Buyers
    • Bargaining Power of Suppliers
    • Threat of Substitutes
    • Threat of New Entrants
  • 11.4 Market Share Analysis

12. Opportunities & Strategic Analysis

  • 12.1 Value Chain Analysis
  • 12.2 Growth Opportunity Analysis
    • 12.2.1 Growth Opportunities by Type
    • 12.2.2 Growth Opportunities by Application
  • 12.3 Emerging Trends in the Global Pharmaceutical Grade Propanesulfolactone Market
  • 12.4 Strategic Analysis
    • 12.4.1 New Product Development
    • 12.4.2 Certification and Licensing
    • 12.4.3 Mergers, Acquisitions, Agreements, Collaborations, and Joint Ventures

13. Company Profiles of the Leading Players Across the Value Chain

  • 13.1 Competitive Analysis
  • 13.2 Changshu Juhe Chemical
    • Company Overview
    • Pharmaceutical Grade Propanesulfolactone Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 13.3 Broahony Group
    • Company Overview
    • Pharmaceutical Grade Propanesulfolactone Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 13.4 Wuhan Jihechang New Material
    • Company Overview
    • Pharmaceutical Grade Propanesulfolactone Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 13.5 Wuhan Pinestone Technology
    • Company Overview
    • Pharmaceutical Grade Propanesulfolactone Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 13.6 Anhui Meisenbao Technology
    • Company Overview
    • Pharmaceutical Grade Propanesulfolactone Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 13.7 Jinan Qinmu Fine Chemical
    • Company Overview
    • Pharmaceutical Grade Propanesulfolactone Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 13.8 Beijing Yuji Science & Technology
    • Company Overview
    • Pharmaceutical Grade Propanesulfolactone Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing

14. Appendix

  • 14.1 List of Figures
  • 14.2 List of Tables
  • 14.3 Research Methodology
  • 14.4 Disclaimer
  • 14.5 Copyright
  • 14.6 Abbreviations and Technical Units
  • 14.7 About Us
  • 14.8 Contact Us
샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제
문의
원하시는 정보를
찾아 드릴까요?
문의주시면 필요한 정보를
신속하게 찾아드릴게요.
02-2025-2992
email
문의하기